Cancer cell stress induced by cytotoxic agents promotes antitumor immune response. Here, we observed that N6-isopentenyladenosine (iPA), an isoprenoid modified adenosine with a well established anticancer activity, was able to induce a significant upregulation of cell surface expression of natural killer (NK) cell activating receptor NK Group 2 member D (NKG2D) ligands on glioma cells in vitro and xenografted in vivo. Specifically suboptimal doses of iPA (0.1 and 1 mM) control the selective upregulation of UL16-binding protein 2 on p53wt-expressing U343MG and that of MICA/B on p53mut-expressing U251MG cells. This event made the glioblastoma cells a potent target for NK cell-mediated recognition through a NKG2D restricted mechanism. p53 siRNA-mediated knock-down and pharmacological inhibition (pifithrin-a), profoundly prevented the iPA action in restoring the immunogenicity of U343MG cells through a mechanism that is dependent upon p53 status of malignancy. Furthermore, accordingly to the preferential recognition of senescent cells by NK cells, we found that iPA treatment was critical for glioma cells entry in premature senescence through the induction of S and G2/M phase arrest. Collectively, our results indicate that behind the well established cytotoxic and antiangiogenic effects, iPA can also display an immune-mediated antitumor activity. The indirect engagement of the innate immune system and its additional activity in primary derived patient's glioma cell model (GBM17 and GBM37), fully increase its translational relevance and led to the exploitation of the isoprenoid pathway for a valid therapeutic intervention in antiglioma research.
p53 has been recently underpinned. [2] [3] [4] In a mouse model of liver carcinoma the pharmacological activation of p53 results in tumor cell senescence and natural killer (NK) celldependent tumor regression 5 as well as in the induction of tumor immunogenicity as reported for primary cell lines derived from patients. 4 This is achieved by the upregulation of UL16-binding protein 2 (ULBP2), a ligand for NK cell activating receptor NK Group 2 member D (NKG2D), an important component of the front line immune defense against infectious diseases and malignancies. 6, 7 Immune escape mechanisms are known to act in synergy to confer an immunosuppressive microenvironment, thus cancer immunotherapy represents a promising anticancer treatment.
Recent studies have shown that GBM may be vulnerable to elements of the innate immune system through its expression of several MHC class I-like stress-associated molecules, such as MHC class I chain-related proteins A and B (MIC-A/B) and human cytomegalovirus membrane glycoprotein (UL-16)-binding proteins. 8 These antigens are recognized by NK cells via the stimulatory receptor NKG2D and by gd Tcells by both NKG2D and T-cell receptors (TCRs) 9 by using innate mechanisms that are MHC independent and that do not require prior antigen exposure or priming. An interesting study highlights that the tumor microenvironment in astrocytomas is commonly associated with CD56-positive NK cells 10 which are also seen to lyse GBM cells in vitro, 11 suggesting to target NK cells as a well defined effector subset against the more aggressive GBM. Nowadays, in fact, a growing number of scientific discoveries into pathways activating or suppressing NK cell function, as well as methods to sensitize tumors to NK cell cytotoxicity, have led to the development of numerous pharmacological and genetic tools to enhance NK cell antitumor immunity. 12 In this context, the new immuneregulatory function of p53 is particularly exciting for cancer therapy research; by greatly enhancing NK-mediated tumor elimination while mediating direct tumor cytotoxicity, it may link immunotherapy to chemotherapy. At the same time it allows to verify the ability of well-known or new genotoxic agents to boost competent immune surveillance mechanisms by altering the antigen presentation capacity of tumor and stromal cells toward immune-stimulation.
N6-isopentenyladenosine (iPA) is a modified nucleoside, formed by an adenosine harboring an isopentenyl chain derived from dimethylallyl pyrophosphate in the N6 position. It belongs to the cytokinin family, involved in the control of many processes in plants. 13, 14 In humans, many biological actions, both in vitro and in vivo can be attributed to iPA. [15] [16] [17] [18] [19] iPA can act directly on cancer growth by inducing the apoptosis of several tumor cells such as colon cancer cells, sarcoma and myeloma cells. 20, 21 Interest in the study of this compound has been reinforced by our recent observations that iPA interferes with the growth of primary glioma cells in vitro and in vivo by selectively downregulating epidermal growth factor (EGFR) oncogene-driven pathways. 22 Furthermore, immunomodulatory properties have also been attributed to iPA, because of its ability to selectively expand and directly target human NK cells and to promote a direct activation of human-resting NK cells. 23 As many widely used anticancer drugs, by initiating stress-response pathway can potentiate immune responses against tumors, here we explore the possibility of enhancing immune-recognition of glioma cells by iPA. Indeed for the first time, we report that iPA, through the establishment of a senescent tumor cell population, was effective in making glioma cells immunovisible and engages the innate immune system to fight their growth through a mechanism that is dependent from p53 status.
Material and Methods

Reagents and abs
iPA (Sigma-Aldrich, St. Louis, MO), was dissolved in DMSO and added to cell cultures at the indicated concentration. Pifithrin-alpha (PFT-a), a selective p53 inhibitor dissolved in DMSO, was obtained from Abcam and was added to cell cultures at the indicated concentration 1 hr before the treatment with iPA. 4 0 -Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-b-D-glucopyranoside), Etoposide, was obtained from Sigma-Aldrich (St. Louis, MO) and was dissolved in DMSO and added to cell cultures at the indicated concentration. The following mAbs were used for immunostaining and FACS analysis: anti-MICA/B/PE, anti-ULBP1/PE, anti-ULBP2/APC, anti-ULBP3/PE, anti-ULBP4/PerCP and anti-human ULBP2/ 5/6 antibody (AF1298) in cytofluorimetric blocking experiments, purchased from R&D Systems (Minneapolis, MN); for immunophenotypic analysis in vivo anti-mouse CD3 and anti-mouse NK1.1 were purchased from eBioscience. In immunohistochemistry, antibodies to MICA, ULBP1 and What's new? Glioblastomas, due to their high frequency of molecular variations, are largely unaffected by standard anticancer therapies. The tumors, however, are potentially vulnerable to immune-mediated tumor inhibition. Here, N6-isopentenyladenosine (iPA), a modified nucleoside that promotes activation of human natural killer (NK) cells, was investigated for its effects on glioblastoma. In human glioma cells and in a glioma mouse model, iPA treatment improved glioma cell immunorecognition via upregulation of NK cell activating receptor NKG2D ligands, leading to senescent tumor cell populations. The findings show that tumor cells can be rendered immunovisible, helping to engage the immune system against glioma growth.
ULBP2 and antibody to Ly49g2 (clone 4D11) to identify infiltrating cells were purchased from BD Biosciences (San Jose, CA). For Western blot analysis the following antibodies were used: rabbit polyclonal anti-human b-actin and rabbit polyclonal anti-human MICA-B were purchased from Abcam (Cambridge, UK), mouse monoclonal anti-human a-tubulin from Sigma-Aldrich (St. Louis, MO), rabbit polyclonal p53, rabbit polyclonal antibody to phosphorylated p53, rabbit polyclonal anti-human phospho-STAT3 (p-STAT3; Tyr705), rabbit monoclonal anti-human STAT3, rabbit monoclonal anti-human p21 and rabbit polyclonal anti-human Hystone H3 were purchased from Cell Signaling Technology (Danvers, MA). Secondary HRP-linked goat anti-mouse or goat antirabbit IgG, were also purchased from Cell Signaling Technology (Danvers, MA).
Cells line culture and treatment. The human glioma cell lines U251MG and U343MG were obtained from CLS Cell Lines Service GmbH (Eppelheim, Germany). The human glioma cell line U87MG was kindly provided by Dr. Daniela Parolaro (U87MG) (University of Insubria, Italy). Human glioma cell lines were cultured in EMEM (Lonza) supplemented with 10% heat-inactivated fetal bovine serum (Euroclone), 1% L-glutamine, 1% antibiotic mixture, 1% sodium pyruvate, 1% non-essential aminoacids (Euroclone). The human osteosarcoma cell line, Saos-2 was obtained from Interlab Cell Line Collection (ICLC Genova, GE, Italy). The cells were cultured in DMEM (Lonza) supplemented with 10% heatinactivated fetal bovine serum and 2 mM L-glutamine (Hyclone Laboratories, Logan, UT) (Euroclone).
Small pieces of brain tissue containing tumor were collected at the time of craniotomy for tumor resection at the Neurosurgery Service of "G. Rummo" Medical Hospital (Benevento, Italy) and the Neurosurgery Service of "San Giovanni di Dio Ruggi d'Aragona" Medical Hospital (Salerno, Italy). The samples were immediately processed to generate primary tumor cell lines. A second sample from each patient was also taken for clinical diagnosis performed by expert neuropathologists in accordance with the International Classification of CNS tumors drafted under the auspices of the World Health Organization (WHO). All tissue samples were collected in accordance with the ethical standards of the Institutional Committee (DEL. N8548 04/20/2007, April 3, 2013). The patients had been informed about the establishment of cellular models from their tumor and had given informed consent in written form. The preparation of adherent primary cultures of brain tumor cells (designated as GBMn) was conducted as reported elsewhere. 22 Human primary peripheral or tumor-infiltrating NK cells were negatively selected by immunomagnetic procedure (NKcell isolation kit; Miltenyi Biotec, Calderara di Reno, Italy), respectively, from peripheral blood mononuclear cells (PBMC) of healthy donors or from cell suspension derived from gentle homogenization of human GBM and cultured for 5 days in RPMI 1640 (Invitrogen, San Diego, CA) supplemented with 2 mM L-Glutamine, 50 ng/ml streptomycin, 50 units/ml penicillin and 10% heat-inactivated fetal bovine serum (Hyclone Laboratories, Logan, UT) in the presence of IL-2 at 100 U/ml alone (Roche Applied Science, South San Francisco, CA). All donors gave written informed consent in accordance with the Declaration of Helsinki to the use of their residual buffy coats for research purposes, with approval from the University Hospital of Salerno Review Board. Peripheral blood mononuclear cells (PBMCs) were isolated over Ficoll-Hypaque gradients (lymphocyte separation medium; MP Biomedicals, Aurora, OH).
All cell cultures were maintained at 378C in humidified 5% CO 2 atmosphere.
Determination of GBM cell proliferation. U251MG cells or U343MG (4 3 10 3 /well), were cultured for 24 hr into 96-well plates before addition of iPA at the indicated concentrations and cultured for additional 24 hr at 378C. Cell proliferation was evaluated by measuring BrdU incorporation into DNA (BrdU colorimetric assay kit; Roche Applied Science, South San Francisco, CA). Newly synthesized BrdU-DNA was determined by an ELISA plate reader (ThermoScientific) at 450 nm. All experiments were performed in triplicate, and the relative cell growth was expressed as a percentage in comparison with the untreated control cells (100%).
Cell cycle analysis. U251MG and U343MG glioma cell lines were plated in 100-mm dishes. To synchronize cells at the G1/S interface, they were serum starved in medium with 0.5% serum for 18 hr. Cells were treated with iPA (0-20 lM). After 24 hr, cells were collected, fixed in 70% ethanol and kept at 2208C overnight. Propidium iodide (PI; 50 lg/ ml) in PBS containing 100 U/ml DNase-free RNase was added to the cells for 15 min at room temperature. Cells were acquired by a FACS Calibur Flow Cytometer (BD Biosciences, San Jose, CA). The analysis was performed with ModFit LT v3.2 (Verity Software House, Topsham, ME); 10, 000 events, corrected for debris and aggregate populations, were collected.
Senescence-associated acidic b-galactosidase staining.
U343MG and U251MG cells were cultured in a six-well plate overnight in standard culture medium and then treated with iPA for 7 days. Medium was aspirated and cells were washed, fixed and stained using a senescence b-Galactosidase staining kit purchased from Millipore. Four high-power fields per sample were counted in three independent samples to score the number of senescence cells. Flow cytometric assay of NK-cell cytotoxicity. Cytotoxicity assays were performed using the fluorescent carboxyFluorescein Diacetate c'FDA NK assay in which cell lysis was analyzed by flow cytometry. Briefly, U251MG, U343MG, GBM17 and GBM37 glioma cells, stimulated as indicated, were labeled by incubation at 10 6 /ml in PBS with 3 lM c'FDA (Molecular Probes-Invitrogen, Paisley, UK). IL-2 activated effector NK cells were mixed with and titrated on the target cells and incubated at 378C for 4 hr in 96-well roundbottom plates (Falcon, Becton Dickinson) in a final volume of 200 ll RPMI 1640 complete medium/well in a humidified 5% CO 2 atmosphere. In parallel, target cells were incubated alone to measure spontaneous cell death. At the end of the incubation time, the total contents of the U-bottom plate were transferred to Falcon tubes, put in ice and incubated with PI, 30 lg/ml for 10 min, followed by flow cytometric analysis within 1 hr. During data acquisition, a "live gate" was set on a c'FDA-stained target cell population using a FL1 histogram, and 5,000 target events were collected. For data analysis, target cells (R1) were analyzed further in a F1/F3 dot plot, where dead target cells (c'FDA 1 PI1) were visualized on the upper-right quadrant. The percentage of target cell death (cytotoxicity) was calculated as follows: cytotoxicity (%) 5 dead target cells in the sample (%) -spontaneously dead target cells (%) 3 100/100 -spontaneously dead target cells (%). All determinations were made in triplicate, and E:T ratios ranged, as indicated in the text. In blocking experiments, anti-human ULBP2/5/6 antibody (R&D Systems, Minneapolis, MN) and LEAF TM purified anti-human MICA/ MICB (6D4) and LEAF TM purified Mouse IgG2a j as isotype control (BioLegend, San Diego, CA) were added at 10 mg/ml 2 hr before starting coincubation effector:target and maintained in culture for additional 4 hr till to the end of the experiment. All determinations were made in triplicate at the indicated E:T ratios (5:1).
Determination of IFN-g by ELISA. For IFN-g secretion measurement, human purified NK cells were stimulated with IL-2 (100 IU/ml). After 72 hr, activated NK cells were washed twice and mixed with untreated or iPA-treated glioma target cells in 200 ll of complete medium. Cells were incubated for the indicated time. Thereafter, supernatants were collected and stored at 2208C pending measurement. The concentration of IFN-g was measured by ELISA assay according to manufacturer's specification (R&D Systems, Minneapolis, MN). Cells were treated in triplicates, and ELISA was done in duplicates for each cell sample.
Mice experiments
We used U87MG cell line in the tumor xenograft models because this cell line has been widely used due to their tumorigenicity in nude mice. The U251MG cells did not show any tumorigenicity in nude mouse in the initial attempts to establish xenograft model. Athymic CD1-deficient nude mice were purchased from Charles River Laboratories (Sulzfeld, Germany). Female mice of 6-8 weeks old were used in all the experiments. The experiments were performed according to NIH guidelines, Guide for the care and Use of laboratory Animals. Mice were bred at Animal research Facility of Biogem scarl, Institute for Genetic Research "Gaetano Salvatore" (Ariano Irpino Avellino, Italy), in accordance with Institutional Statement for the Use of Animals in cancer research.
U87 luciferase expressing GBM cells (luc-U87) were provided by Biogem scarl. Before the implant, the cells were expanded, evaluated for contaminations and vitality, counted and resuspended in M199 medium. Cells were inoculated subcutaneously (s.c.) in the right flank region at a concentration of 5 3 10 6 /100 ml/mouse. Treatments began 9 days after injection. The day before the first administration (day 21) mice were subdivided in tumor volume (TV) homogeneous groups of treatment (N 5 10-12 each) in the following experimental groups: control (intraperitoneal injection of vehicle, 3 times a week for 4 weeks) and iPA (intraperitoneal administration of 50 lg/mouse iPA, 3 times a week for 4 weeks). Mice were daily monitored for clinical signs and mortality. Body weight recordings were carried out 2 times a week. Tumor growth was monitored 2 times a week with a Mitutoyo caliper. The formula TV (mm 3 ) 5 [length (mm) 3 width (mm) 2 ]/2 were used, where the width and the length are the shortest and the longest diameters of each tumor, respectively. The end of the experiment was fixed at 6 weeks after the injection. After 41 days, at the end of experiment, all animals for each group were sacrificed by cervical dislocation. Explanted masses were weighted and photo recorded and used for immunohistochemistry while spleens were collected in complete medium for the determination and characterization of splenic NK lymphocytes.
Immunohistochemistry
Cryosections (0, 7 mm) of luc-U87 explanted masses prepared at Day 41 were fixed in acetone and blocked with 2% normal rabbit serum and 2% BSA. Tissue sections were stained with antibodies (1:50) to MICA, ULBP1, ULBP2 and Ly49G2 (Becton Dickinson, San Jose, CA). A 1:150 biotinylated anti-rat secondary antibody (Zymed, San Francisco,
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CA) was used. Avidin-biotin complex was added, and the staining was developed with diaminobenzidine.
Quantitative real-time PCR. Total RNA was isolated using the NucleoSpin Q7 RNA II kit (Macherey-Nagel). Complementary DNA (cDNA) was transcribed using SuperScript II Reverse Transcriptase (Invitrogen), starting from 1 lg of high pure RNA. Genes expression profiles were evaluated with specific primer sets and using SsoFast EvaGreen reagents (Bio-Rad), b2-microglobulin was used as housekeeping gene. qRT-PCR protocol was: a preheating step for 3 min at 958C, 40 cycles at 958C for 10 sec and 608 for 30 sec and last end-step at 658C for 10 sec. Results were analyzed with 2-DDCt method. Primer sets were the following: MICAFw GACTTGACAGGGAACGGAAA, MICARev CAGGTTTTG-GGAGAGGAAGA; MICBFw CAGCTACTGGGTCCACTGGT, MICBRev GTTGGTCATGATCCCTTTGC; ULBP1Fw CGGT-GCTAATGGATGGAACT, ULBP1Rev TGGTCAGTGCAT-CAAAAGGA; ULBP2Fw TCAAACTCGCCCTTCTGTCT, ULPB2Rev GTGCAGGAATTCCATCAGGT; ULBP3Fw CTG-GGGAAAACAACTGGAAA, ULBP3Rev ATCGAAGCTGAA-CTGCCAAG; and the house keeping gene was the b2-microglobulin: b2Fw CCTGGATTGCTATGTGTCTGG, b2Rev GGAGCAACCTGCTCAGATACA or b-actin: ActinFw CACT-GTGCCCATCTACGAGG, ActinRev TGGCCATCTCTTGCT-CGAAG.
Cell transfection with plasmid constructs. Human p53 expression plasmids pCMV-p53wt and pCMV-p53 R273H plasmid was purchased by Addgene (Cambridge, MA).
U251MG cells and Saos-2 cells at 90% of confluence were transfected with 3 lg of pCMVp53 plasmid using Lipofectamine 2000 (DNA/Lipofectamine ratio was 1/2.5) according to manufacturer's instructions. 24 hr after transfection, at maximum of expression of p53, they were treated with iPA at selected concentration for additional 24 hr prior to FACS analysis.
U343MG cells were transfected with 5 lg of mut(R273H)p53 plasmid using Lipofectamine 2000 (DNA/ Lipofectamine ratio was 1/2.5) according to manufacturer's instructions. 24 hr after transfection they were treated with iPA at selected concentration for additional 24 hr.
Six hours after transfection, incubation medium was replaced with fresh and FBS supplemented medium. Control cells were transfected with empty vector (mock).
siRNA-mediated knockdown. P53 siRNA transfection was carried out according to manufacturer's instructions. First, siRNAp53 (#106141, Invitrogen) and negative control siRNA (Silencer Negative Control, Ambion) were dissolved in Opti-MEM serum-free media. Both p53 and scrambled siRNA were delivered into the U343MG cell cultures plated 18 hr prior (approximately 80% confluency) via Lipofectamine RNAiMAX reagent (Invitrogen). The final concentration of p53 and scrambled siRNA in culture was 100 nM. The cells were incubated with the transfection reagents for 48 hr and iPA was added to silenced cells in the last 24 hr. At the end of 48 hr, the cells were then harvested for analysis of protein knockdown and iPA effects via Western blot.
Western blot analysis
For analysis of protein levels from cells they were grown in p60 tissue culture plates at a density of 2 3 10 4 cells/cm 2 for 24 hr. Tumor cells were then incubated with vehicle, iPA, Etoposide, PFT-a or combined as indicated. After incubation cells were washed with PBS, harvested and lysed in ice-cold RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100, 0.5% deoxycholic acid, 10 mg/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride and 10 mg/ml aprotinin). After removal of cell debris by centrifugation (14,500 g for 20 min at 48C), the proteins were estimated. About 30 mg of proteins was loaded on 10, 12 or 15% SDS-polyacrylamide gels under reducing conditions and then transferred to nitrocellulose membranes. The blots were blocked with 5% nonfat dry milk (Bio-Rad, Richmond, CA) in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 hr at room temperature and incubated with the specific antibody. Immunodetection of specific proteins was carried out with horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit IgG (Biorad, Hercules, CA), using the enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech, Piscataway, NJ) according to the manufacturer's instructions and then exposed to X-ray film (Amersham Biosciences). To ascertain equal protein loading in WB, membranes were probed with an antibody raised to a-tubulin (Sigma-Aldrich, St. Louis, MO) or b-actin (Abcam, Cambridge, UK).
Subcellular fractionation
Nuclear and cytoplasmic extracts were prepared with an isotonic lysis buffer (150 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl, at pH 7.5, 0.5% NP-40; Complete protease inhibitor cocktail). Cells were harvested in ice-cold lysis buffer and centrifuged at 700g for 7 min at 48C. The supernatant was further clarified by centrifugation at 13,000g for 15 min at 48C, representing the cytoplasmic fraction. The pellet was suspended in ice-cold nuclear lysis buffer (250 mM NaCl, 20 mM sodium phosphate at pH 7.0, 30 mM sodium pyrophosphate, 5 mM EDTA, 10 mM NaF, 0.1% NP-40, 10% glycerol, 1 mM dithiothreitol, Complete protease inhibitor cocktail) and sonicated three times for 15 sec. The supernatant was clarified by centrifugation at 13,000g for 15 min at 48C, representing the nuclear fraction. Separation of the nuclear and cytoplasmic fractions was verified by blotting with the cytosolic protein anti-a-tubulin and the nuclear protein anti-Hystone H3 antibodies.
Statistical analysis
Statistical analysis was performed in all the experiments shown by using the GraphPad prism 6.0 software for Windows (GraphPad software). For each type of assay or phenotypic analysis, data obtained from multiple experiments are calculated as mean 6 SD and analyzed for statistical significance using the two-tailed Student's t test, for independent groups, or ANOVA followed by Bonferroni correction for multiple comparisons. p values <0.05 were considered significant. *p < 0.05, **p < 0.01 and ***p < 0.001.
Results
iPA inhibits glioma cells proliferation through p53 activation
Based on previous observations suggesting that iPA inhibited cell proliferation of several cancer cell lines, we started to test iPA for its ability to inhibit the growth of human glioma cells. To this end, two GBM cell lines, U343MG cells expressing wild type p53 and U251MG cells with mutant p53 (R273H) were incubated with different concentrations of iPA ranging from 0.1 to 20 lM for 24 hr. As demonstrated by BrdU incorporation assay, the treatment with iPA induced a pronounced dose-dependent inhibition of U343MG and U251MG cell proliferation. For U343MG cells concentration lower than 10 lM is already effective, while in U251MG cells, it was between 5 and 10 mM (Fig. 1a) . In order to evaluate which phase of U343MG and U251MG glioma cells proliferation was affected by iPA, we investigated cell cycle distribution of these cells following iPA treatment for 24 hr through flow cytometric analysis. As shown in Figure 1b , the percentage of cells in S and G2/M phases were slighter higher both in U343MG and U251MG glioma cells following iPA treatment (0.1-20 mM), suggesting that the antiproliferative effects of iPA might be related to the arrest in S and G2/M phase.
As recently discussed, the rapid accumulation of G2 cells with a higher DNA content might be the consequence of cell cycle exit after G2 arrest following cellular stresses. 24 As the "G2 exit program" often results in a form of irreversible journey to senescence, we then carried out microscopy analysis to visualize the senescence-associated b-galactosidase (SA-bGal) activity. 25 Consistent with this possibility, glioma cells displayed a clear blue staining compared to control cells after 7 days of treatment of iPA. Suboptimal doses of the compound are the more effective, confirming the induction of a senescent phenotype in U343MG and more pronounced in U251MG cells (Fig. 1c) . Of note, the activation of the senescence program occurred indipendently of the cellular p53 status as U343MG cells expressed p53 wt , while U251MG were p53 mut . Because p53 is one the major mediator of the cellular response to stress signals mainly by inducing the cyclin dependent kinase inhibitor p21, iPA induced an expected increase of p53 and p21 in p53 wt U343MG cells but not in the p53 mut U251MG which showed no response on p53 level neither to iPA neither to etoposide used as positive control of p53 induction (Fig. 1d) . Indeed as reported in literature for many cancers, we found that mutant p53 accumulated to high levels in U251 without inducing p21 target gene, index of the lack of its activity. On the contrary in p53 wt U343 cells the dinamic accumulation of p53 with or without iPA correlate with a linear increase in p21 levels. Accordingly to the results of SA-b-Gal assay, in U343MG cells an increase of p53 activity was observed in response to very low concentrations (0.1 and 1 mM) of iPA without an apparent dosedependent effect (Fig. 1d, upper panel) .
As the triggering of this important safeguard mechanism already occurred at low concentrations, we decided to use 0.1 and 1 mM iPA for the next experiments investigating the dinamic upregulation of stress-inducible ligands frequently accompained to a premature senescence state. Furthermore, we chose these experimental range concentrations to also beneficiate from the NK immunostimulatory effects of iPA, achieved at submicromolar doses as previously reported by our group. Since it has been recently described that p53 activation can evoke an antitumor immune response through the induction of NKG2D ligand ULBP2, 4, 26 we investigated the effect of iPA on the surface expression of NKG2D ligands on U343MG GBM cells and in turns on NK cell recognition and cytotoxicity against these cancer cells as target. Then by flow cytometry, we monitored the cell surface expression of the NKG2D ligands MICA/B, ULBP1, ULBP2, ULBP3 and ULBP4 on untreated and iPA-treated U343MG glioma cells at 24 hr. We found that the incubation with low doses of iPA (0.1 and 1 mM) induced a selective upregulation of ULBP2 surface expression (Fig. 2a) , reaching its statistical significance both in terms of mean fluorescence intensity (MFI) and in terms of total percentage of positive cells (Fig.  2b) and without any significant effect on MICA/B, ULBP1, ULBP3 and ULBP4 levels.
Then, by real-time PCR, we verified whether the ULBP2 upregulation on U343MG cells could be the consequence of an increased mRNA expression. Interestingly, we observed a significant increase in ULBP2 mRNA expression in U343MG cells following iPA treatment (Fig. 2c) . No significant changes of MICA, MICB, ULBP1, ULBP3 and ULBP4 transcripts were detected in the same conditions (data not shown). Cytotoxic assay was then performed to address the effect of ULBP2 induction by iPA on NK cell recognition and killing of U343MG glioma cells. As expected, the pretreatment of U343MG cells with iPA significantly increased specific killing (Fig. 2d) and IFN-g secretion (Fig. 2e) by cocultured NK cells, when compared with the cytotoxic activity of control untreated cells (Figs. 2d and 2e) .
The RNA interference and the pharmacological inactivation of p53 counteracts the anticancer innate immune response triggered by iPA in U343MG cells Since p53 activation is involved in the induction of ULBP2, first we investigated whether the inhibition of p53 could suppress ULBP2 induction by pretreatment of U343MG cells with PFT-a, a known pharmacological inhibitor of p53
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Ciaglia et al. Figure 3a , the pretreatment with PFT-a in U343MG cells treated with iPA 1 lM prevented the accumulation of p53 in the nucleus and significantly decreased iPA-induced ULBP2 expression in terms of MFI (Fig. 3b) . The dependence on p53 of these iPA effects was also true for NK immune recognition of iPA-treated U343MG cells. Indeed, the increase in specific killing induced by iPA was considerably reduced in the presence of PFT-a (Fig. 3c) . As an alternative approach, the silencing of p53 in U343MG cells, whose efficacy is shown in the left panel of Figure 3d , significantly In a next step, we wondered whether the ability of iPA to upregulate ULBP2 and to enhance the NK cell degranulation might be affected in mut p53-expressing U251MG glioma cells under the same conditions. Interestingly, even though to a lower degree than in U343MG cells, iPA also increased the immunogenicity of treated U251MG cells. Indeed as showed in Figure 4a , the degranulation of NK cells was significantly increased in coculture with U251MG cells pretreated with iPA. However, the observed changes in U251MG specific lysis were not due to a specific effect of the compound on ULBP2. Indeed, FACS analysis revealed that ULBP2 surface expression was not altered by iPA treatment (Fig. 4b) ; on the contrary, iPA was responsible for a substantial upregulation of MICA/B molecules as revealed by the increase in the levels both of MFI and percentage of positive cells (Fig. 4c) . To corroborate these findings and to demonstrate the specificity of the observed effects, we investigated the cell signaling pathways that might mediate the response to iPA in U251MG. Recently, a role for the transcription factor STAT3 in the regulation of MICA/B expression has been described. 27, 28 In accordance to the biological effects observed, Western blot analysis showed that the treatment with iPA increased the expression of MICA by selectively reducing Tyr705 phosphorylation of its transcriptional repressor STAT3 in U251MG cells. Remarkably, all these molecular events were evident in U251MG cells but not in U343MG glioma cell line (Fig. 4d) .
activity. As shown in
The p53 status of glioma cells dictates the different effect of iPA on ULPB2 and MICA/B induction
We found significant p53-dependent induction of ULBP2 transcription by iPA, as it was only detected in wt p53-expressing U343MG cells but not in p53 mut-expressing ones; additionally, we documented iPA effect on MICA/B levels that seems to be p53-independent and STAT3 related. To corroborate these findings and give more insights into the immunomodulatory action of iPA for the control of p53 wt and p53 mut malignancy, we finally investigated the effects of the ectopic expression of mutant p53 in U343MG cells and alternatively that of wt p53 in U251MG cells on NKG2D ligands. As expected, the transfection of mut p53 in U343MG cells prevented the induction of ULBP2 by iPA while increasing the basal level of MICA/B surface expression. Here the 
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coexistence of two different form of p53 may explain the lack of statistical significance in the achieved effects along the inability of iPA to upregulate MICA/B molecules on the trasfected cells (Fig. 5a, upper panel) . At the same way, the wt p53-transfected U251MG glioma cell line expressed not significant increased basal levels of ULBP2 but, more importantly it failed to upregulate MICA/B molecules in response to iPA (Fig. 5a , lower panel). These results suggest that iPA treatment might improve the immunorecognition of glioma cells by inducing the NKG2D ligand ULBP2 on p53 wt or alternatively MICA/B on p53 mut malignancies. As an alternative approach, in order to confirm the importance of p53 status for iPA effect, we transiently transfected the Saos-2 (p53 null) human osteosarcoma cell line with pCMV-p53wt plasmid. In line with an earlier report, 29, 30 MICA was the most frequently expressed NKG2D ligand in parental cells and iPA 1 mM increased its level by reducing the activation of STAT3 at 18 hr (Fig. 5b) . At this time point the overexpression of a functional p53 restored the p21 levels and consistently reduced the MICA expression both in basal condition and upon treatment with iPA. Finally, the ability of iPA to significantly increase p53 activity, as suggested by the accumulation of p53 and p21 at later time point (24 hr), led to selectively upregulate the ULBP2 levels on surface of transfected cells, compared to the effects on parental ones (Fig.  5c) . Then, to further corroborate the selective upregulation of NKG2D ligands on the two differents glioma cell lines, the contribution of ULBP2 and MICA/B in the NK cell cytotoxicity triggered, respectively, by iPA-treated U343MG and iPA- (Fig. 5d) . On the contrary, in U251MG cells anti-MICA/B but not anti-ULBP2 was able to reduce NK cells lysis to basal level (Fig. 5e) , suggesting that NK cell cytotoxic capacity was dependent on recognition of MICA/B, which was specifically upregulated on the surface of U251MG cells by iPA treatment.
iPA treatment induces the expression of NKG2D ligands on surface of glioma patient-derived primary cells in vitro and in U87-xenografted mice in vivo
To test iPA efficacy in a more physiopathological context ex vivo, we moved to characterize phenotypic responses of two representative glioma patients-derived cell lines (GBM37 and GBM17) to iPA treatment. Of these, GBM17 showed no response on p53 level and here iPA induced comparable changes as observed in U251MG glioma cell line (MICA/B upregulation vs. ULBP2). On the contrary in GBM37, who displayed a correct p53 signaling, iPA induced surface upregulation of ULBP2 but not of MICA/B, which was comparable to that observed in U343MG cell line (Figs. 6a and 6b) . Accordingly, cytotoxicity of brain tumor-infiltrating NK from the two representative patients against the autologous primary cell lines (GBM37 and GBM17) was significantly increased by iPA pretreatment (Fig. 6c) , underscoring the therapeutic relevance of our findings. Finally, as a proof of concept, this mechanism seems to be valid also in a subcutaneous xenograft model in vivo. The U251MG cells did not show a considerable tumorigenicity in nude mice in the initial attempts to establish a xenograft model, so we choosed U87 glioma cells as this cell line is commonly used due to their higher tumorigenicity reported in nude mice. Explorative immunophenotypic analysis of p53wt-expressing U87MG cells in vitro confirmed the specific upregulation of ULBP2 but not of MICA/B on the surface of iPA-treated cells (Fig. 6d) . Then 24 nude mice were injected s.c. with U87 cells. When tumors size reached approximately 4-6 mm in diameter, 12 mice were injected intraperitoneally with 50 mg iPA three times a week for 4 weeks, while 12 mice in control group received vehicle alone (PBS). After 41 days from treatment beginning, four animals for each group were sacrificed for immunohistological analysis. Consistent with our in vitro observations, IHC revealed that iPA preferentially upregulated the expression of ULBP2 in the p53 wt-expressing U87 xenograft compared to the control group (Fig. 6e) . Interestingly, at the microscopic examination of tumor xenograft slices, iPA-treated mice also showed a massive presence of inflammatory cells compared to control group. Of note, immunohistochemical staining for the inhibitory Ly49G2 receptor, 
whose expression is predominantly restricted on mouse activated NK cells, 31 revealed a good degree of immunoreactivity for this marker in the tumor xenograft of both control and iPA-treated animals. Accordingly, flow cytometric analysis on splenic lymphocytes revelead no significant changes in the number of NK cells, identified as CD3-NK1.1 lymphocytes, after drug treatment at the selected dose (ip, 50 lg/mouse) (Fig. 6f) . This highlightes the ability of iPA to not induce lymphopenia, which may increase the translational impact and therapeutic potential of the isoprenoide derivative.
Discussion
GBM is the most common and highly malignant brain tumor. Despite current treatment with surgery, radiation therapy and chemotherapy, most patients have a poor prognosis, since malignant glioma is also one among the most therapyresistant human neoplasias. Therefore, novel therapeutic strategies for treating this disease are strongly required. Although preliminary clinical results have not been translated into significantly better survival, very recent phase II trials are exploring the combination of multitargeted drugs with cytotoxic chemotherapy and radiotherapy in order to overcome the resistance of tumors to single-agent targeted therapies. 32 Among other potential novel therapies, cellular immunotherapy, remains an attractive approach. 33 Precisely in the past few years, increasing evidence has suggested to take advantage of the anticancer immune response contributing to the control of tumors after conventional chemotherapy; indeed, different observations have indicated that chemotherapeutic agents or radiotherapy can induce specific immune response that results in immunogenic cancer cell death or immunostimulatory side effects. 34, 35 The upregulation of NKG2D ligands, and consequently, the immune recognition by NKG2D-expressing lymphocytes (including NK cells, NKT cells, CTL, gd T cells) induced by several genotoxic agents [36] [37] [38] are example of the new intriguing functional connection between chemotherapy and therapeutical immunomodulation. We and others have previously reported cytotoxic, antiangiogenic and proapoptotic activity of iPA in different cell lines. 17, 18, [20] [21] [22] 39 Recently, a surprising antiglioma effect was also documented in vitro and in vivo model, where the isoprenoide derivative act through the specific degradation of EGFR and downregulation of cell signaling pathways dependent from the growth factor receptor oncogene. Further, in xenograft tumors induced by k-ras transformed thyroid cells (KiMol), this natural cytokinine has been shown to exert a similar antiproliferative action by inhibiting the farnesyl pyrophosphate synthase (FPPS). Recently, we described the marked activity of its isoprenoid derivative N6-benzyladenosine (CM223) in selectively targeting glioma cells but not normal human astrocytes through a FPPS-dependent protein prenylation blocking, 40 suggesting that this class of isoprenoid end products might be used for antineoplastic therapy, an application emulating that of the lovastatin and/or farnesyl-transferase inhibitors. 20 In analogy to the unique specificity for phosphoantigens, such as the isopentenyl pyrophosphate, shown by human Vg9Vd2 T cells, we also reported for the first time the additional ability of iPA to selectively expand and directly target human NK cells, in part due to the fine modulation of FPPS activity. 23 Accordingly to the immunomodulatory potential of some antitumoral compounds, in this study, we described for iPA the surprising ability to increase the immunogenicity of glioma target cells. Indeed, beyond to interfere with common oncogenic processes related to cell cycle progression and survival, iPA treatment, by improving the immunorecognition of glioma cells through the NKG2D ligand ULBP2 on p53 wt (U343MG and primary GBM37) or alternatively MICA/B on p53 mut (U251MG and primary GBM17) malignancies, may offer a multi target control of glioma and eventually other tumors against which previously it has been shown to have cytotoxic effects.
Looking for mechanism of iPA action, we identified p53 and possibly STAT3 as molecular targets which mediate upregulation of ULBP2 and MICA/B, respectively, in tumors where they are frequently overexpressed. 9 Because of the central role of tumor suppressor and oncogenes in the pathogenesis of cancer, it is unsurprising that these might be the main candidates for the induction of NKG2DL expressed in transformed cells. Moreover, as these two transcription factors control different processes of carcinogenesis and tumor survival 2,41 along with a recently reported immunomodulatory properties, 4, 26, 27 their targeting may constitute the molecular base of iPA dual activity on anticancer cell extrinsic and intrinsic barriers. Indeed, by activating p53 function, iPA not only affects cancer growth but also stimulates the expression of ULBP-2 on p53 wt-expressing tumor cells. Notably, iPA is also able to ensure an immune control of p53 mut-expressing cells. Here in fact, in accordance with Soriani and collegues who provided evidence indicating that p53 was not involved in MICA/B drug-induced induction, as consequence of ROSdependent DNA damage response, 42 iPA, through MICA/B upregulation makes the p53 mut U251MG cells immunovisible, engaging the innate immune system to fight them at the same way of U343MG cells. STAT3 transcription factor seems to be implicated in such effect, as iPA significantly reduces its phosphorylation levels in U251MG cells (Fig. 4d) but we cannot rule out the regulation of glycogen synthase kinase-3-catenin for which a role in the regulation of MICA/ B expression by HDAC inhibitor has been also described. 43 Finally, we wanted to identify the trigger event of these two different kind of immunogenic responses. Recently, it has been shown that activation of the ATM/ATR protein kinases by DNA Damage can result in upregulation of certain NKG2D ligands 9 in both p53-positive and p53-null cells in an ATM-and ATR-dependent fashion. 44 Interestingly in HUVEC in vitro cell model of angiogenesis, we previously experienced cell cycle arrest and apoptosis by iPA after the activation of typical DNA damage checkpoints, such as the ATR-Chk1 pathway and p53. 18 To date, eventhough it is unknown whether the observed effects in U343MG cells are dependent from this DNA damage signaling pathway, it is possible that iPA induces a cellular stress whose result in terms of expression of immunostimulatory molecules is strictly dependent on p53 status of glioma cells. Regardless the mechasnims, the NKG2D ligands found upregulated on iPA-treated glioma cells belong to a family of stress-inducible ligands whose expression can be ascribed to a condition of a cellular stress which frequently trigger senescence and recently, a role for NK cells in the immune surveillance of senescent cells has been pointed out in liver fibrosis, 45 hepatocellular carcinoma 46 and multiple myeloma. 36 Accordingly, iPA-treated cells are arrested in G 2 /M cell-cycle phase (Fig.  1b) and by acquiring a senescent phenotype (Fig. 1c) , become more visible and suscetible to NK cell-mediated immune clearance in a NKG2D-dependent manner (Fig. 5b) .
Concerning the biological significance of the differential upregulation of ULBP2 and/or MICA/B NKG2D ligands, common sense suggests that it can be the result of evolution to maximize the efficiency of immune recognition of malignancies. Indeed, the killing by NK cells is dependent on the strenght of signal; this can result from the inhibitory and activating receptors competitions, but also from different qualitatively signals and the avidity of receptor engagment. There are similarities and differences between MIC and ULBP molecules that may help to understand the biology of these proteins and therefore the impact of NKG2D ligand expression on tumor control. Interestingly, biocore analysis indicated that the strenght of NKG2D ligand-mediated signaling correlates with the stability of the ligand-receptor complex. In mice NKG2DL have different binding affinities and they are not equal in their capacity to activate the NKG2D receptor. 47 In humans by surface plasmon-resonance (SPR) methods, Pingwei Li's group demonstrated that NKG2D-MICA interaction is relatively more stable than TCR-ligand and other NCR-ligand complex, 48 causing a more intense tyrosine phosporylation pattern in NK cells than ULBP. 49 Then, we can speculate that while ULBP is sufficient to control p53 wt expressing cells, MICA/B is indispensable to patrol the most aggressive p53 mut expressing ones. In chronic myeloid leukemia, for example, the BCR/ ABL (breakpoint cluster region/abelson) fusion oncoprotein induces the expression of MICA on the surface of leukemic cells, but it is absent on hematopoietic CD341 cells from healthy donors. 50 Of particular interest the dependence on the cellular metabolic status of differential expression of the various NKG2D-ligand has been also highlighted. 51 An emerging striking observation is that p53 is able to contribute to the regulation of several metabolic pathway as oxidative phosphorylation, glutaminolysis, insulin sensitivity, nucleotide biosynthesis, fatty acid oxidation and mevalonate pathway, as recently described by our group. 52 We believe that this may corroborate our findings and configure p53 status as a key molecular signature in dictating the different effect on ULPB2 and MICA/B induction by iPA but more generally by stress stimuli.
All these findings, along the well established antitumor effects, provide evidence for the possibility to restore both innate immune response and cell autonomous effect against glioma by iPA. Moreover, as it acts on mevalonate (MEV) pathway, our observations provide additional information that pharmacological modulation of intermediate enzymes of the pathway could potentiate the activity of NK and cytotoxic immune cells against tumor (Figs. 6b and 6c) , via mechanism that can involve a parallel action on tumor cells and immune compartment. Indeed, MEV pathway for cholesterol biosynthesis and protein prenylation has been implicated in various aspects of tumor development and progression. In addition recent discoveries concerning isoprenoid dysregulation as a novel type of danger signal alerting the immune system, which reacts to phosphorylated isoprenoid metabolites to achieve a protective antitumor response, underpin its important contribution to tumor immune surveillance, too. 53 Therefore, the fine modulation of this pathway might be really exploited for novel combined chemo-immunotherapeutic strategies. The lack of lymphopenia as adverse side effect in vivo (Fig. 6f) , its additional activity in primary derived patient's glioma cell model (GBM17 and GBM37), together with its ability to selectively activate NK cells at the same selected concentration, 23 fully increase the translational relevance of iPA. Indeed iPA itself or its derivatives might be useful experimental therapeutics in antiglioma fight where, given at high dosage of attack, can destroy tumor cells and then, at low doses of maintenance, guarantee a long lasting immunesurveillance. Because different aspects of glioma biology have been separately targeted with very limited success, iPA capable of tumoral cell division control while making the glioma immunovisible and engaging the immune system to fight it, may represent a hopeful alternative to other established chemotherapeutics approaches.
